Literature DB >> 24833095

Decreased ARID1A expression facilitates cell proliferation and inhibits 5-fluorouracil-induced apoptosis in colorectal carcinoma.

Chengyao Xie1, Lin Fu, Yong Han, Qingchang Li, Enhua Wang.   

Abstract

AT-rich interactive domain 1A (ARID1A) is a key member of the SWI/SNF chromatin-modeling complex, and the gene has emerged as a tumor suppressor in various human cancers. In the present study, we investigated the expression pattern of ARID1A in human colorectal carcinoma. We found that ARID1A expression was decreased in colorectal carcinoma compared with normal tissue. Loss of ARID1A significantly correlated with poor differentiation (p = 0.0009). We also explored the involvement of ARID1A in the biological behavior of colorectal cancer cell lines. ARID1A overexpression by plasmid transfection in SW620 cell line inhibited proliferation and facilitated 5-fluorouracil-induced apoptosis. ARID1A depletion by siRNA in SW480 cell line promoted proliferation ability and inhibited 5-fluorouracil-induced apoptosis. Furthermore, we found that ARID1A regulated the activity of Akt signaling pathway. In conclusion, our data suggested that ARID1A serves as an important tumor suppressor in colorectal carcinoma and regulates proliferation and chemoresistance of colorectal cancer cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24833095     DOI: 10.1007/s13277-014-2074-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  40 in total

Review 1.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

2.  Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance.

Authors:  Xianyu Zhang; Youxue Zhang; Yanmei Yang; Ming Niu; Shanshan Sun; Hongfei Ji; Yuyan Ma; Guodong Yao; Yongdong Jiang; Ming Shan; Guoqiang Zhang; Da Pang
Journal:  Cancer Epidemiol       Date:  2011-09-01       Impact factor: 2.984

3.  Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.

Authors:  Bin Guan; Tsui-Lien Mao; Pradeep K Panuganti; Elisabetta Kuhn; Robert J Kurman; Daichi Maeda; Elizabeth Chen; Yung-Ming Jeng; Tian-Li Wang; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

4.  Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.

Authors:  Kimberly C Wiegand; Anna F Lee; Osama M Al-Agha; Christine Chow; Steve E Kalloger; David W Scott; Christian Steidl; Sam M Wiseman; Randy D Gascoyne; Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2011-05-18       Impact factor: 7.996

5.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

6.  The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest.

Authors:  Norman G Nagl; Antonia Patsialou; Dale S Haines; Peter B Dallas; George R Beck; Elizabeth Moran
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

Review 7.  The SWI/SNF complex and cancer.

Authors:  D Reisman; S Glaros; E A Thompson
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

8.  ARID1A: a potential prognostic factor for breast cancer.

Authors:  Jing Zhao; Caigang Liu; Zuowei Zhao
Journal:  Tumour Biol       Date:  2014-01-16

9.  The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma.

Authors:  Zheng-mao Zhang; Shuang Xiao; Guang-yu Sun; Yue-ping Liu; Feng-hua Zhang; Hong-fang Yang; Jia Li; Hong-bing Qiu; Yang Liu; Chao Zhang; Shan Kang; Bao-en Shan
Journal:  Int J Gynecol Cancer       Date:  2014-03       Impact factor: 3.437

10.  Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Authors:  Siân Jones; Meng Li; D Williams Parsons; Xiaosong Zhang; Jelle Wesseling; Petra Kristel; Marjanka K Schmidt; Sanford Markowitz; Hai Yan; Darell Bigner; Ralph H Hruban; James R Eshleman; Christine A Iacobuzio-Donahue; Michael Goggins; Anirban Maitra; Sami N Malek; Steve Powell; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Hum Mutat       Date:  2011-11-23       Impact factor: 4.878

View more
  10 in total

1.  TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance.

Authors:  Zhi-Feng Miao; Zhen-Ning Wang; Ting-Ting Zhao; Ying-Ying Xu; Jian-Hua Wu; Xing-Yu Liu; Hao Xu; Yi You; Hui-Mian Xu
Journal:  Virchows Arch       Date:  2015-02-28       Impact factor: 4.064

2.  Deletion of Arid1a in Reproductive Tract Mesenchymal Cells Reduces Fertility in Female Mice.

Authors:  Xiyin Wang; Shikha Khatri; Russell Broaddus; Zhong Wang; Shannon M Hawkins
Journal:  Biol Reprod       Date:  2016-03-09       Impact factor: 4.285

3.  Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.

Authors:  Qian Zhang; Hai-Bo Yan; Jie Wang; Shu-Jian Cui; Xiao-Qing Wang; Ying-Hua Jiang; Li Feng; Peng-Yuan Yang; Feng Liu
Journal:  Oncotarget       Date:  2016-07-19

Review 4.  Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-analysis.

Authors:  Young-Sik Kim; Hoiseon Jeong; Jung-Woo Choi; Hwa Eun Oh; Ju-Han Lee
Journal:  Saudi J Gastroenterol       Date:  2017 Sep-Oct       Impact factor: 2.485

5.  The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature.

Authors:  Anaïs Chauvin; Chang-Shu Wang; Sameh Geha; Perrine Garde-Granger; Alex-Ane Mathieu; Vincent Lacasse; François-Michel Boisvert
Journal:  Clin Proteomics       Date:  2018-04-13       Impact factor: 3.988

6.  Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.

Authors:  Supharada Tessiri; Anchalee Techasen; Sarinya Kongpetch; Achira Namjan; Watcharin Loilome; Waraporn Chan-On; Raynoo Thanan; Apinya Jusakul
Journal:  PeerJ       Date:  2022-01-13       Impact factor: 2.984

Review 7.  Roles of ARID1A variations in colorectal cancer: a collaborative review.

Authors:  Shankun Zhao; Weizhou Wu; Zufu Jiang; Fuqin Tang; Lingzhi Ding; Weifang Xu; Libin Ruan
Journal:  Mol Med       Date:  2022-04-14       Impact factor: 6.354

8.  A radiosensitizer, gallotannin-rich extract from Bouea macrophylla seeds, inhibits radiation-induced epithelial-mesenchymal transition in breast cancer cells.

Authors:  Jiraporn Kantapan; Siwaphon Paksee; Aphidet Duangya; Padchanee Sangthong; Sittiruk Roytrakul; Sucheewin Krobthong; Wipob Suttana; Nathupakorn Dechsupa
Journal:  BMC Complement Med Ther       Date:  2021-07-03

9.  Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency in Vitro.

Authors:  Lin Yang; Guanghai Yang; Yingjun Ding; Yuhong Dai; Sanpeng Xu; Qiuyun Guo; Aini Xie; Guangyuan Hu
Journal:  J Cancer       Date:  2018-02-25       Impact factor: 4.207

Review 10.  Actionable Potentials of Less Frequently Mutated Genes in Colorectal Cancer and Their Roles in Precision Medicine.

Authors:  Ryia Illani Mohd Yunos; Nurul Syakima Ab Mutalib; Francis Yew Fu Tieng; Nadiah Abu; Rahman Jamal
Journal:  Biomolecules       Date:  2020-03-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.